메뉴 건너뛰기




Volumn 17, Issue 10, 2014, Pages 708-718

Consequences of patient access restrictions to branded oxycodone hydrochloride extended-release tablets on healthcare utilization and costs in US health plans

Author keywords

Access restriction; Chronic pain; Cost; ER LA opioid; Prior authorization; Tier change; Utilization

Indexed keywords

OXYCODONE;

EID: 84907292890     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.925464     Document Type: Article
Times cited : (7)

References (37)
  • 1
    • 84907283727 scopus 로고    scopus 로고
    • American Academy of Pain Medicine. Accessed August 13
    • American Academy of Pain Medicine. http://www.painmed.org/patientcenter/facts-on-pain.aspx#refer. Accessed August 13, 2013
    • (2013)
  • 2
    • 80053201781 scopus 로고    scopus 로고
    • Relieving pain in America, a Blueprint for Transforming, Prevention, Care, Education and Research The National Academies Press, Washington DC
    • Relieving pain in America, a Blueprint for Transforming, Prevention, Care, Education and Research. Institute of Medicine Report from the Committee on Advancing Pain Research, The National Academies Press, Washington, DC. 2011.
    • (2011) Institute of Medicine Report from the Committee on Advancing Pain Research
  • 3
    • 67650755014 scopus 로고    scopus 로고
    • A comparison of long-and short-acting opioids for the treatment of chronic noncancer pain: Tailoring therapy to meet patient needs
    • Argoff C, Silvershein D. A comparison of long-and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clinic Proc 2009;84:602-12
    • (2009) Mayo Clinic Proc , vol.84 , pp. 602-612
    • Argoff, C.1    Silvershein, D.2
  • 4
    • 58949087497 scopus 로고    scopus 로고
    • Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain
    • Chou R, Fanciullo G, Fine P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
    • (2009) J Pain , vol.10 , pp. 113-130
    • Chou, R.1    Fanciullo, G.2    Fine, P.3
  • 5
    • 84907283726 scopus 로고    scopus 로고
    • The United States Food and Drugs Admi nistration News Release. Accessed April 29
    • The United States Food and Drugs Admi nistration News Release. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367726. htm. Accessed April 29, 2014
    • (2014)
  • 6
    • 84907283725 scopus 로고    scopus 로고
    • The United States Food and Drugs Administration. Goal of label changes: better prescribing, safer use of opioids Washington DC, USA. Accessed April 30, 2014
    • The United States Food and Drugs Administration. Goal of label changes: better prescribing, safer use of opioids. 2013. Washington DC, USA. http://www.fda.gov/forconsumers/consumerupdates/ucm367660.htm. Accessed April 30, 2014
    • (2013)
  • 7
    • 84907283724 scopus 로고    scopus 로고
    • The United States Food and Drugs Administration. List of ex tended-release and long-acting opioid products required to have an opioid REMS. Washington DC, USA. Accessed April 20
    • The United States Food and Drugs Administration. List of ex tended-release and long-acting opioid products required to have an opioid REMS. Washington DC, USA. http://www.fda.gov/drugs/drugsafety/Informationbydrugclass/ucm251735.htm. Accessed April 20, 2014
    • (2014)
  • 8
    • 84907283723 scopus 로고    scopus 로고
    • United St ates Department of Justice. Drug Enforcement Agency. Drug scheduling. Washington DC, USA. Accessed August 13
    • United St ates Department of Justice. Drug Enforcement Agency. Drug scheduling. Washington DC, USA. http://www.justice.gov/dea/druginfo/ds.shtml. Accessed August 13, 2013
    • (2013)
  • 9
    • 84907283627 scopus 로고    scopus 로고
    • Purdue Pharma Oxycontin Full Prescribing Information 2014. Stamford, CT, USA. Accessed April 20
    • Purdue Pharma. Oxycontin Full Prescribing Information 2014. Stamford, CT, USA. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022272s022lbl.pdf. Accessed April 20, 2014
    • (2014)
  • 10
    • 84907283626 scopus 로고    scopus 로고
    • Academy of Managed Care Pharmacy, Common practice in formulary management systems. Academy of Managed Care Pharmacy Alexandria, VA, USA. Accessed April 28, 2014
    • Academy of Managed Care Pharmacy, Common practice in formulary management systems. Academy of Managed Care Pharmacy, 2000. Alexandria, VA, USA. http://www.amcp.org/WorkArea/DownloadAsset. aspx?id= 9274. Accessed April 28, 2014
    • (2000)
  • 11
    • 84860741571 scopus 로고    scopus 로고
    • Pharmaceutical technology assessment: Perspectives from payers
    • Leung M, Halpern M, West N. Pharmaceutical technology assessment: perspectives from payers. JMCP 2012;18:256-64
    • (2012) JMCP , vol.18 , pp. 256-264
    • Leung, M.1    Halpern, M.2    West, N.3
  • 12
    • 84881670427 scopus 로고    scopus 로고
    • Deciding which drugs get onto the formulary: A value-based approach
    • Seigfried R, Corbo T, Saltzberg M, et al. Deciding which drugs get onto the formulary: a value-based approach. Value Health 2013;16:901-6
    • (2013) Value Health , vol.16 , pp. 901-906
    • Seigfried, R.1    Corbo, T.2    Saltzberg, M.3
  • 13
    • 12144266162 scopus 로고    scopus 로고
    • Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population
    • Delate T, Mager, DE, Sheth J. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. AJMC 2005;11:29-36
    • (2005) AJMC , vol.11 , pp. 29-36
    • Delate, T.1    De, M.2    Sheth, J.3
  • 14
    • 56049086018 scopus 로고    scopus 로고
    • Prior authorization for biologic diseasemodifying antirheumatic drugs: A description of US Medicaid programs
    • Fischer M, Polinski J, Servi A, et al. Prior authorization for biologic diseasemodifying antirheumatic drugs: a description of US Medicaid programs. Arthritis Rheum 2008;59:1611-7
    • (2008) Arthritis Rheum , vol.59 , pp. 1611-1617
    • Fischer, M.1    Polinski, J.2    Servi, A.3
  • 15
    • 44449114349 scopus 로고    scopus 로고
    • Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change
    • Soumeria S, Zhang F, Ross-Degnan D, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Affairs 2008;27:185-95
    • (2008) Health Affairs , vol.27 , pp. 185-195
    • Soumeria, S.1    Zhang, F.2    Ross-Degnan, D.3
  • 16
    • 77958139493 scopus 로고    scopus 로고
    • Impact of prior authorization for pregabalin on health plan drug expenditures
    • Bazalo G, Weiss R, Joshi A. Impact of prior authorization for pregabalin on health plan drug expenditures. AJMC 2010;16:S154-9
    • (2010) AJMC , vol.16 , pp. S154-S159
    • Bazalo, G.1    Weiss, R.2    Joshi, A.3
  • 17
    • 77954096052 scopus 로고    scopus 로고
    • Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans
    • Margolis J, Cao Z, Onukwugha W, et al. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. AJMC 2010;16:447-56
    • (2010) AJMC , vol.16 , pp. 447-456
    • Margolis, J.1    Cao, Z.2    Onukwugha, W.3
  • 18
    • 44449116226 scopus 로고    scopus 로고
    • Medicaid prior authorization and controlledrelease oxycodone
    • Morden N, Zerzan J, Rue T, et al. Medicaid prior authorization and controlledrelease oxycodone. Med Care 2008;46:573-80
    • (2008) Med Care , vol.46 , pp. 573-580
    • Morden, N.1    Zerzan, J.2    Rue, T.3
  • 19
    • 84877925015 scopus 로고    scopus 로고
    • Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain
    • Merchant S, Noe L, Howe A, et al. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain . Clin Therapeut 2013;35:359-72
    • (2013) Clin Therapeut , vol.35 , pp. 359-372
    • Merchant, S.1    Noe, L.2    Howe, A.3
  • 20
    • 84907283625 scopus 로고    scopus 로고
    • US Department of Health and Human Services. Food and Drug Adminstration. FDA actions on OxyContin Products 4/16/2013. FDA news release 2013. Washinton DC. Accessed September 26
    • US Department of Health and Human Services. Food and Drug Adminstration. FDA actions on OxyContin Products 4/16/2013. FDA news release 2013. Washinton DC., http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.htm, Accessed September 26, 2013
    • (2013)
  • 21
    • 0026639706 scopus 로고
    • Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
    • Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9
    • (1992) J Clin Epidemiol , vol.45 , pp. 613-619
    • Deyo, R.A.1    Cherkin, D.C.2    Ciol, M.A.3
  • 22
    • 27744568384 scopus 로고    scopus 로고
    • Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
    • Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
    • (2005) Med Care , vol.43 , pp. 1130-1139
    • Quan, H.1    Sundararajan, V.2    Halfon, P.3
  • 26
    • 84866644230 scopus 로고    scopus 로고
    • Clinical policy: Critical issues in the prescribing of opioids for adult patients in the emergency department
    • Cantrill S, Brown M, Carlisle R, et al. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. Ann Em erg Med 2012;60:499-525
    • (2012) Ann em Erg Med , vol.60 , pp. 499-525
    • Cantrill, S.1    Brown, M.2    Carlisle, R.3
  • 27
    • 84884181958 scopus 로고    scopus 로고
    • Opioid use and abuse: A pain clinic perspective
    • Schultz D. Opioid use and abuse: a pain clinic perspective. Minn Med 2013;96:42-4
    • (2013) Minn Med , vol.96 , pp. 42-44
    • Schultz, D.1
  • 28
    • 84879358492 scopus 로고    scopus 로고
    • Opioids for the management of non-cancer pain
    • Nelsen D. Opioids for the management of non-cancer pain. J Ark Med Soc 2013;109:252-3
    • (2013) J Ark Med Soc , vol.109 , pp. 252-253
    • Nelsen, D.1
  • 29
  • 30
    • 84884174675 scopus 로고    scopus 로고
    • Finding a feasible solution states employ different legislative strategies to curb misuse
    • Milhofer J. Finding a feasible solution. States employ different legislative strategies to curb misuse. Minn Med 2013;96:52-4
    • (2013) Minn Med , vol.96 , pp. 52-54
    • Milhofer, J.1
  • 31
    • 84884218515 scopus 로고    scopus 로고
    • A call for evidence-based medical treatment of opioid dependence in the United States and Canada
    • Nosyk B, Anglin M, Brissette S, et al. A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Aff 2013;32:1462-9
    • (2013) Health Aff , vol.32 , pp. 1462-1469
    • Nosyk, B.1    Anglin, M.2    Brissette, S.3
  • 33
    • 0033710389 scopus 로고    scopus 로고
    • What is the real cost of prior authorization
    • Reissman D. What is the real cost of prior authorization? Drug Benefit Trends 2000;12:22-4
    • (2000) Drug Benefit Trends , vol.12 , pp. 22-24
    • Reissman, D.1
  • 34
    • 84907283624 scopus 로고    scopus 로고
    • Manage medical advances with automated prior authorization
    • Accessed November 20, 2013
    • Moeller D. Manage medical advances with automated prior authorization. Managed Executive 2009. http://managedhealthcareexecutive.modernmedicine. com/mhe/article/articleDetail.jsp?id=615491. Accessed November 20, 2013
    • (2009) Managed Executive
    • Moeller, D.1
  • 35
    • 34250875798 scopus 로고    scopus 로고
    • Prior authorization of newer insomnia medications in managed care is it cost saving
    • Balkrishnan R, Joish V, Bhosle MJ, et al. Prior authorization of newer insomnia medications in managed care: is it cost saving? J Clin Sleep Med 2007;3:393-8
    • (2007) J Clin Sleep Med , vol.3 , pp. 393-398
    • Balkrishnan, R.1    Joish, V.2    Bhosle, M.J.3
  • 36
    • 0033869399 scopus 로고    scopus 로고
    • A comparison of two methods for estimating the health care costs of epilepsy
    • Frost FJ, Hurley JS, Petersen HV, et al. A comparison of two methods for estimating the health care costs of epilepsy. Epilepsia 2000;41:1020-6
    • (2000) Epilepsia , vol.41 , pp. 1020-1026
    • Frost, F.J.1    Hurley, J.S.2    Petersen, H.V.3
  • 37
    • 77954715172 scopus 로고    scopus 로고
    • Cost of diabetes: Comparison of diseaseattributable and matched cohort cost estimation methods
    • Tunceli O, Wade R, Gu T, et al. Cost of diabetes: comparison of diseaseattributable and matched cohort cost estimation methods. CMRO 2010;26:1827 -34
    • (2010) CMRO , vol.26 , pp. 1827-1834
    • Tunceli, O.1    Wade, R.2    Gu, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.